1 tablet

19 cents

Persantin, Pytazen

  • Adjunct to oral anticoagulants in circumstances where there is high risk of thrombosis

PO:
Immediate Release Tablets:
25mg tablets (orange)
Twice Daily Sustained Release Tablets and Modified Release Capsules:
Pytazen SR 150mg tablets (yellow), Persantin Perlongets 150mg Capsules (pink/white)


ADULT DOSE
PO / NG:
Usual dosage 150mg of sustained release twice a day (or equivalent daily dose of immediate release tablets divided and administered 6 to 8 hourly). Use immediate release tablets if administering via NG tube.

PAEDIATRIC DOSE
PO
1-2mg/kg 6-8 hourly oral
See PRECAUTIONS
Paediatric Use

DOSAGE IN RENAL FAILURE AND RENAL REPLACEMENT THERAPY
Dose as in normal renal function

Platelet aggregation inhibitor

CONTRAINDICATIONS

  • Hypersensitivity to dipyridamole


WARNINGS
See PRECAUTIONS

PRECAUTIONS
General:
Coronary Artery Disease:
Dipyridamole has a vasodilatory effect and should be used with caution in patients with severe coronary artery disease (e.g., unstable angina or recently sustained myocardial infarction). Chest pain may be aggravated in patients with underlying coronary artery disease who are receiving dipyridamole.
Hepatic Insufficiency:
Elevations of hepatic enzymes and hepatic failure have been reported in association with dipyridamole administration.

Hypotension:
Dipyridamole should be used with caution in patients with hypotension since it can produce peripheral vasodilation.

Laboratory Tests:
No tests in addition to standard ICU tests are required

Drug/Laboratory Test Interactions:
None known

Adenosine:
Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary.
Cholinesterase Inhibitors:
Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.

Body as a Whole:
Fatigue, malaise, myalgia
Neurological System:
Headache
Cardiovascular System:
Hypotension, palpitations, and tachycardia
Respiratory System:
severe bronchospasm, larynx oedema, angioedema
Gastrointestinal System:
Cholelithiasis, nausea, diarrhoea, vomiting, hepatitis.
Dermatological System:
Rash, urticaria
Haematological System:
Thrombocytopaenia

[an error occurred while processing this directive]